Tuesday, August 4, 2020
News
NEWS HOME
»
PRESS RELEASES

EUSA Pharma Announces FDA Approval of Phase 3 Clinical Trial for Siltuximab in Hospitalized Patients With COVID-19 Associated Acute Respiratory Distress Syndrome
  SocialTwist Tell-a-Friend  
   


Date: 02-07-2020 1:50PM
Source: EUSA PHARMA
Category: General, Science & Research, Healthcare & Biotechnology, Pharmaceutical, Technology
Location: Hemel Hempstead, United Kingdom & Burlington, Mass., United States

Business Wire India

EUSA Pharma, a global biopharmaceutical company focused on oncology and rare disease, today announced that the U.S. Food & Drug Administration (FDA) has approved a randomized, double-blind, placebo-controlled Phase 3 clinical trial protocol to evaluate the safety and efficacy of intravenous siltuximab plus standard of care in hospitalized patients with COVID-19 associated Acute Respiratory Distress Syndrome (ARDS).

Siltuximab is a monoclonal antibody that directly neutralizes interleukin (IL)-6, an inflammatory cytokine detected at elevated levels in multiple inflammatory conditions, including COVID-19. It specifically binds to IL-6, thereby inactivating IL-6 induced signalling.

Lee Morley, Chief Executive Officer, EUSA Pharma, said:“Since the start of the pandemic, a growing body of evidence has been published highlighting that COVID-19 associated ARDS may exhibit features of systemic hyperinflammation, resulting from excessive cytokine production – the so-called ‘cytokine storm’ – with IL-6 recognized as a key driver of this severe condition. Treatment approaches neutralizing IL-6 could therefore play a key role in mitigating further detrimental inflammation and progression to respiratory failure, which can be fatal. We thank the FDA for recognizing the importance of this clinical trial and the quick approval we received. Our plan now is to initiate the study as quickly as possible with the hope of seeing improved clinical outcomes in these critically ill patients.”

To date, several independent clinical trials have begun globally to explore the safety and efficacy of siltuximab for the treatment of severe COVID-19 patients. Final results from the Papa Giovanni XXIII Hospital sponsored SISCO1 (Siltuximab In Serious COVID-19) Study, an observational cohort control trial investigating siltuximab plus standard of care in COVID-19 patients with serious respiratory complications, are available via pre-print summary here.2 However, the newly approved confirmatory clinical trial is vital because these findings require validation in a well-controlled randomized study and there is limited published data on the safety and efficacy of siltuximab in COVID-19. Siltuximab is also not yet FDA-approved for complications associated with COVID-19.

About the New Clinical Trial

EUSA Pharma has received FDA approval to proceed with a randomized, double-blind, placebo-controlled Phase 3 clinical trial to evaluate the safety and efficacy of intravenous siltuximab plus standard of care in hospitalized patients with COVID-19 associated ARDS, compared to placebo plus standard of care. The multicentre trial will aim to enrol approximately 400 patients with viral ARDS and elevated serum levels of IL-6. The primary objective is to evaluate all-cause mortality at 28 days with the addition of siltuximab to standard of care, compared to placebo plus standard of care. Secondary objectives include: time to 7-category ordinal scale of clinical status improvement, ventilator-free days within 28 days, organ failure-free days, intensive care unit length of stay, hospital length of stay, lung function and radiographic improvement.

About SYLVANT®? (siltuximab)

SYLVANTis an IL-6 targeted monoclonal antibody approved by the FDA and the European Medicines Agency (EMA) as well as regulatory bodies in a number of other jurisdictions worldwide, for the treatment of patients with multicentric Castleman disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative (also known as idiopathic MCD). EUSA Pharma has exclusive rights to SYLVANTglobally. EUSA Pharma has granted BeiGene, Ltd., exclusive development and commercialization rights to SYLVANTin Greater China.

SYLVANT is not licensed for the treatment of COVID-19.

Indications and Usage of SYLVANT – See Full Prescribing Information for Additional Details.

SYLVANTis indicated for the treatment of patients with MCD who are HIV negative and HHV-8 negative.

Limitations of Use: SYLVANT was not studied in patients with MCD who are HIV positive or HHV-8 positive because SYLVANT did not bind to virally produced IL-6 in a nonclinical study.

Contraindications: Severe hypersensitivity reaction to siltuximab or any of the excipients in SYLVANT.

Dosage and Administration

Administer SYLVANT 11 mg/kg over 1 hour as an intravenous infusion every 3 weeks until failure.

Perform hematology laboratory tests prior to each dose of SYLVANT therapy for the first 12 months and every 3 dosing cycles thereafter. If treatment criteria outlined in the Prescribing Information are not met, consider delaying treatment with SYLVANT. Do not reduce dose.

Do not administer SYLVANT to patients with severe infections until the infection resolves.

Discontinue SYLVANT in patients with severe infusion related reactions, anaphylaxis, severe allergic reactions, or cytokine release syndromes. Do not reinstitute treatment.

About EUSA Pharma

Founded in March 2015, EUSA Pharma is a world-class biopharmaceutical company focused on oncology and rare disease. The company has extensive commercial operations in the United States and Europe, alongside a direct presence in select other markets across the globe. EUSA Pharma is led by an experienced management team with a strong record of building successful pharmaceutical companies, and is supported by significant funding raised from leading life science investor EW Healthcare Partners. For more information please visit: www.eusapharma.com.

References

1 An Observational Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications (SISCO) [NCT04322188]: https://www.clinicaltrials.gov/ct2/show/NCT04322188

2 IL-6 Signalling Pathway Inactivation With Siltuximab in Patients With COVID-19 Respiratory Failure: an Observational Cohort Study. Gritti et al; medRxiv 2020.04.01.20048561; doi: https://doi.org/10.1101/2020.04.01.20048561



CONTACTS :

Lee Morley
Chief Executive
EUSA Pharma
Email: covid.press@eusapharma.com

Barney Mayles
Associate Director
OPEN Health
Email: barneymayles@openhealthgroup.com
Mobile: +44 (0)7936 768568

More Press Releases

Moody’s Analytics Repeats IFRS 9 Wins at Risk Technology Awards

First Eagle to Open Its First German Office in More Than 80 Years; New Hire Louanges Will Direct International Wholesale Business From Munich

Hengli Petrochemical Announces Start-up of its 5th PTA Line Utilising INVISTA’s P8 PTA Technology

Dole Unveils Integrated Strategy Against Banana Disease

Spykke Innovations Partners with tracesafe, to Launch Unique COVID Safety Wristbands in India

Freedom for Our Girls: Breaking Menstrual Barriers

Takeda Announces FY2020 Q1 Results; Confirms Management Guidance & Raises Reported Operating Profit And Reported Net Profit for the Full Year

Craft Silicon and PayU Announce Strategic Association to Advance Digital Loan Repayment Solutions for Lending Institutions

With World’s 1st AI and ML Powered Annual-Recurring-Subscription-Model, Frinza Is All Set to Disrupt the Global Gifting Industry

Crossbeats Brings You Work from Home’s Best Bud in Its Beast of a New True Wireless Earphones

Preferred Equity Offering of Lead Real Estate via a Digital Securities Issuance, Brought to Market by GRIP, Securitize and Rialto

Andersen Global Continues West African Expansion with Addition of Tax and Legal Firm in Benin

New One-Stop Resource Center Gives Developers a Robust Array of Tools to Easily Manage, Monitor and Integrate Limelight Services

India Angel Fund invests in Mental Wellness Startup IPHM Services, round led by Monaliesa Sarkar, Jyoti Tiwari, Koel Dutta, Sabana Khatoon, Dr. Vikaas Grover and Rahul Narvekar

CoinEx $50M Ecosystem Development Fund Points First Investment as OneSwap

Wipro Selected as Strategic Partner by Metro Bank to Drive IT Transformation

Velodyne Lidar Sensors Power Emesent’s Hovermap to Fly Beyond the Visual Line of Sight

Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trialin adults with and without diabetes

Takeda Announces U.S. FDA Breakthrough Therapy Designation Granted for Pevonedistat for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

NWFI Says Everyone is Looking at India as an Alternative to China and Allowing Exports Will Boost the Domestic Industry

UL Issues First Safety Mark for Hyperbaric Chambers in India

Abbott and 1mg Bring Continuous Glucose Monitoring Solutions Closer to Indian Homes

Face Mask Killing Covid-19, Tested by US-Based ISO Certified Laboratory, Developed and Launched by an Indian Start-up

Terns Pharmaceuticals Announces Completion and Positive Results from Phase 1 Clinical Trial of TERN-201, a SSAO Inhibitor in Development for NASH

Philips Introduces Revolutionary Haircare High-Tech Devices and DIY Female Grooming Products

Taobao Introduces Maker Rating System to Champion Young Entrepreneurs, Originality

Sustainable Mica Policy and Vision Prepared by Responsible Mica Initiative with Jharkhand Government and Civil Society Support

MOGAS Wins Multimillion Dollar Bid to Supply Valves for Southeast Asian Refinery

Bank of Baroda’s Credit Card Arm Readies for Digital Transformation with Implementation of Fiserv Technology

Aspect Announces General Availability of Aspect Unified IP 7.4 SP1, the Premier Enterprise Contact Center Solution for High Volume Customer Outreach

Recipe for Growth: Balancing Health, Indulgence and Taste Key to Drive Biscuit and Cookie Growth in India

Automation Industry Leader, Armstrong Along With Indian Rocket Scientists Launched UWe Safe for Contactless 3D Sanitization

WorldRemit Wishing All Those Celebrating a Blessed Eid al Adha

DNSC Introduces the “Typhoon” C20590 MX, the World’s Lowest Cost 100 ppm Full-Color All-In-One MICR Inkjet System

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Lt Gov sets up special court for trial o...
Chennai man attempts to break Guinness W...
Steady improvement in Karnataka's COVID ...
Tripura CM undergoes COVID-19 test after...
Do not allow IPL in Dubai, CAIT urges Sh...
Former Karnataka CM Siddaramaiah tests p...
More...    
 
 Top Stories
Former Karnataka CM Siddaramaiah te... 
Karnataka: Crime Branch arrests 7 f... 
BMC curtails bus services in Mumbai... 
COVID-19 pandemic "once in a centur... 
UK's Covid count reaches 305,623... 
China reports 36 new coronavirus ca... 
Bombay HC to hear plea seeking tran... 
Senior CPI-M leader Md Salim tested...